Comparative Pharmacology
Head-to-head clinical analysis: TESSALON versus TUZISTRA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESSALON versus TUZISTRA XR.
TESSALON vs TUZISTRA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzonatate is a local anesthetic structurally related to tetracaine that inhibits pulmonary stretch receptors and reduces the cough reflex by decreasing the sensitivity of vagal afferent fibers in the respiratory tract.
Tuzistra XR is a combination of codeine (an opioid agonist) and promethazine (a phenothiazine derivative with antihistaminic, sedative, and anticholinergic effects). Codeine binds to mu-opioid receptors in the CNS, inhibiting cough reflex. Promethazine acts as a histamine H1 receptor antagonist and may have additional central anticholinergic and sedative effects.
100 mg orally three times daily as needed for cough. Maximum 600 mg/day.
Initial: 25 mg orally twice daily; may increase to 50 mg twice daily after 1 week based on tolerability; maximum 50 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in adults; significant interindividual variability. No accumulation with q6h dosing.
Terminal elimination half-life is 7 hours for the parent drug; clinically, this supports twice-daily dosing for sustained symptom relief.
Renal: <5% unchanged; primary route is hepatic metabolism with metabolites excreted renally and fecally; exact biliary/fecal % not established in humans.
Primarily hepatic metabolism via glucuronidation; approximately 20% of the dose is excreted unchanged in urine, and 80% is eliminated as metabolites in feces via biliary excretion.
Category C
Category C
Antitussive
Antitussive/decongestant combination